Antineoplastic / Chemotherapeutic agent / Anthracyclines

Strength: 3.5 mg
Packaging: Vial
Indication: for the treatment of adult patients with multiple myeloma (MM), as monotherapy in patients who have received at least one prior therapy and as part of combination induction therapy in previously untreated patients eligible for stem cell tran...

Description: Oral targeted anticancer medication containing ibrutinib, used in the treatment of various B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma.

Therapeutic Category: Antineoplastic / Targeted Therapy

...

Single use vial ampoule containing azacitidine 100 mg freeze dried powder for IV/SC infusion. Antineoplastic, DNA Methylation Inhibitor

Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes covering the common range of patient specifi c doses for economy and convenience Cabazitaxel is a third-generation antineoplastic taxane and was the fi rst therapy to show a survival benefi t fo...

Pemetrexed for Injection is a folate-dependent antineoplastic agent that disrupts folate-dependent metabolic processes essential for cell replication. It is used in the treatment of malignant pleural mesothelioma and non-small cell lung cancer.

Pack Strengths Available: 100 mg, 500 mg
qq...

Features • Individual, customized and very flexible design 
• Compact – low space requirements  
• Low hold-up volume, smaller wetted area 
• Greatly reduced deadlegs 
• All blocks are designed for optimized draining and machined from one block of material&nbs...

We offer a wide range of API products which include Dasatinib monohydrate and Dasatinib anhydrous. It belongs to oncology category. Therapeutic category: molecular targeted. Regulatory status for Dasatinib monohydrate:USDMF No. 23763, USFDA Approved, Stability Studies Zone IVB, WC available ...

intermediates

Heraeus Precious Metals business line Pharmaceutical Ingredients provides a wide range of active pharmaceutical ingredients, which includes Oxaliplatin. Contact us for more information.

50mg daily: Combination with luteinizing hormone releasing hormone (LHRH) analogs or surgical orchiectomy for the treatment of advanced prostatic carcinoma.

150mg daily: For the treatment of patients with locally advanced prostate cancer without distant metastasis, who are unsuitable or unwillin...

The Walk-In Cooling Cabinets / cold rooms are designed according to ICH guidelines, WHO, MCA and USFDA requirements to maintain uniform conditions. They are superior in airflow distribution, temperature control technology, cabinet construction and are manufactured as per cGMP regulations.
Biggest Walk...

ARaymondlife has developed the essential accessory for drug reconstitution, the vial adapter, one for each RayDyLyo diameter. The RayDyLyo® vial adapter is a medical device intended for the quick and safe reconstitution of drugs, contained in vials capped with RayDyLyo® plastic press fit caps, a...

Oncology drugs/adjuvant antitumor drugs.CAS NO.24584-09-6,
Standard: In-house

This medication is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells

Indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation

AOS Products Pvt Ltd have a commitment to bring human closer to nature so that all can be benefited by it. Most of the essential Oils are therapeutic in nature, Only the aroma of these oils helps to cure several disorders and diseases. Thus we try hard to keep the natural therapeutic quality of the oil so ...

A niche oncology API used in its finished form (injectable) for the treatment of brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. Available for all global markets except the US along with DMF support.

Finished formulation for General products and Oncology products 

Formulations available in 
-- Tablets 
-- Capsules 
-- Dry powder for suspension 


Products packed in 
-- Blister pack
-- Drum pack 
-- Bottle Pack
-- Sachet 

Oncology API

Each vial contains 245,32 mg fosaprepitant dimeglumin equivalent to 150 mg fosaprepitant (=130,5 mg aprepitant). After reconstitution and dilution, 1 mL of solution contains 1 mg fosaprepitant (1 mg / mL).